10.22
Precedente Chiudi:
$10.31
Aprire:
$10.17
Volume 24 ore:
1.04M
Relative Volume:
0.48
Capitalizzazione di mercato:
$879.40M
Reddito:
$139.71M
Utile/perdita netta:
$-209.36M
Rapporto P/E:
-3.4527
EPS:
-2.96
Flusso di cassa netto:
$-160.60M
1 W Prestazione:
+10.49%
1M Prestazione:
+11.21%
6M Prestazione:
-29.08%
1 anno Prestazione:
-56.10%
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Nome
Syndax Pharmaceuticals Inc
Settore
Industria
Telefono
781-419-1400
Indirizzo
730 THIRD AVENUE, NEW YORK, MA
Confronta SNDX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
SNDX
Syndax Pharmaceuticals Inc
|
10.22 | 887.15M | 139.71M | -209.36M | -160.60M | -2.96 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-07-10 | Iniziato | Goldman | Buy |
2024-10-24 | Iniziato | UBS | Buy |
2024-06-28 | Iniziato | Jefferies | Buy |
2024-01-31 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
2023-12-22 | Iniziato | Mizuho | Buy |
2023-10-25 | Iniziato | BofA Securities | Buy |
2023-10-11 | Iniziato | Goldman | Buy |
2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
2023-07-11 | Iniziato | Guggenheim | Buy |
2023-04-17 | Ripresa | BTIG Research | Buy |
2023-01-31 | Iniziato | Stifel | Buy |
2023-01-03 | Iniziato | JP Morgan | Overweight |
2022-07-28 | Ripresa | B. Riley Securities | Buy |
2022-04-11 | Iniziato | H.C. Wainwright | Buy |
2022-02-15 | Iniziato | Goldman | Buy |
2021-06-04 | Ripresa | Robert W. Baird | Outperform |
2021-05-25 | Iniziato | Citigroup | Buy |
2021-02-18 | Iniziato | B. Riley Securities | Buy |
2020-12-03 | Iniziato | Stifel | Buy |
2020-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
2020-05-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
2020-05-18 | Downgrade | Citigroup | Buy → Neutral |
2020-05-11 | Reiterato | H.C. Wainwright | Buy |
2020-03-04 | Iniziato | Barclays | Overweight |
2020-01-13 | Reiterato | H.C. Wainwright | Buy |
2019-03-08 | Reiterato | H.C. Wainwright | Buy |
2019-01-04 | Iniziato | Robert W. Baird | Outperform |
2018-01-05 | Iniziato | B. Riley FBR, Inc. | Buy |
2017-03-16 | Iniziato | FBR & Co. | Outperform |
2017-03-02 | Iniziato | Instinet | Buy |
2016-10-07 | Iniziato | Guggenheim | Buy |
2016-03-28 | Iniziato | Citigroup | Buy |
2016-03-28 | Iniziato | JMP Securities | Mkt Outperform |
2016-03-28 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Syndax Pharmaceuticals Inc Borsa (SNDX) Ultime notizie
Syndax Pharmaceuticals Inc. Stock Analysis and ForecastDouble-digit growth - Autocar Professional
What analysts say about Syndax Pharmaceuticals Inc. stockHigh-octane investment gains - Autocar Professional
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CFO Keith A. Goldan Sells 1,296 Shares - MarketBeat
Is Syndax Pharmaceuticals Inc. a good long term investmentFree Capital Efficiency Planning - jammulinksnews.com
Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group Acquires New Shares in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
What drives Syndax Pharmaceuticals Inc. stock priceFree Smart Trading Workshop - jammulinksnews.com
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CEO Sells $69,990.86 in Stock - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Teacher Retirement System of Texas - Defense World
Analysts Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) PT at $34.10 - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Cut to $35.00 by Analysts at UBS Group - MarketBeat
Top Executives at Syndax Pharmaceuticals Make Significant Stock Moves! - TipRanks
Syndax Pharmaceuticals Executives Sell Shares for Tax Obligations - TradingView
Is Syndax Pharmaceuticals Inc. stock a good hedge against inflationFree Insider Trading Tips - Newser
Will Syndax Pharmaceuticals Inc. stock benefit from interest rate changesBreakout Confirmation Tool - Newser
(SNDX) Trading Advice - news.stocktradersdaily.com
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 6% Following Analyst Downgrade - MarketBeat
UBS Group Has Lowered Expectations for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price - Defense World
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 6% on Analyst Downgrade - Defense World
Syndax CFO and CEO sell shares at $9.29/share on July 16, 2025. - AInvest
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Syndax’s Revuforj Granted FDA Priority Review for Relapsed/Refractory Mutant NPM1 AML - MSN
Why Syndax Pharmaceuticals Inc. stock attracts strong analyst attentionSmart Growth Low Risk Picks - Newser
What makes Syndax Pharmaceuticals Inc. stock price move sharplyPro Trader Stock Focus - Newser
UBS Lowers Price Target for Syndax Pharmaceuticals (SNDX) to $35 - GuruFocus
How Syndax Pharmaceuticals Inc. stock performs during market volatilityFree Day Trading Recommendations - Newser
UBS Adjusts Price Target on Syndax Pharmaceuticals Inc to $35 From $37, Maintains Buy Rating - MarketScreener
UBS Adjusts Price Target for Syndax (SNDX) While Maintaining Pos - GuruFocus
The Goldman Sachs Group Begins Coverage on Syndax Pharmaceuticals (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals Inc Azioni (SNDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):